6,921 Shares in BioTelemetry, Inc. (BEAT) Acquired by Campbell & CO Investment Adviser LLC
Campbell & CO Investment Adviser LLC purchased a new stake in shares of BioTelemetry, Inc. (NASDAQ:BEAT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,921 shares of the medical research company’s stock, valued at approximately $232,000.
A number of other large investors have also recently made changes to their positions in BEAT. Pembroke Management LTD purchased a new stake in shares of BioTelemetry during the second quarter valued at $9,168,000. Russell Investments Group Ltd. boosted its stake in shares of BioTelemetry by 115.2% in the second quarter. Russell Investments Group Ltd. now owns 970,162 shares of the medical research company’s stock valued at $32,453,000 after buying an additional 519,267 shares during the last quarter. First Midwest Bank Trust Division boosted its stake in shares of BioTelemetry by 1.2% in the second quarter. First Midwest Bank Trust Division now owns 64,566 shares of the medical research company’s stock valued at $2,159,000 after buying an additional 773 shares during the last quarter. Insight Capital Research & Management Inc. purchased a new stake in shares of BioTelemetry during the second quarter valued at $1,309,000. Finally, Dubuque Bank & Trust Co. purchased a new stake in shares of BioTelemetry during the second quarter valued at $142,000. 83.91% of the stock is owned by institutional investors and hedge funds.
BioTelemetry, Inc. (NASDAQ BEAT) traded up 2.22% during midday trading on Friday, hitting $34.50. 404,643 shares of the stock traded hands. The company has a market cap of $1.12 billion, a price-to-earnings ratio of 23.15 and a beta of 0.76. BioTelemetry, Inc. has a 52-week low of $15.25 and a 52-week high of $36.50. The firm’s 50-day moving average is $33.52 and its 200-day moving average is $29.20.
BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.02. The firm had revenue of $58.10 million during the quarter, compared to analyst estimates of $58.39 million. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.20 earnings per share. Analysts predict that BioTelemetry, Inc. will post $0.99 EPS for the current year.
WARNING: “6,921 Shares in BioTelemetry, Inc. (BEAT) Acquired by Campbell & CO Investment Adviser LLC” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://theolympiareport.com/2017/08/12/campbell-co-investment-adviser-llc-takes-position-in-biotelemetry-inc-beat-updated.html.
Several equities research analysts have weighed in on the stock. Zacks Investment Research raised shares of BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 price target for the company in a research report on Friday. Sidoti reissued a “buy” rating and set a $49.00 price target (up previously from $42.00) on shares of BioTelemetry in a research report on Thursday. Dougherty & Co increased their price target on shares of BioTelemetry from $37.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday. BidaskClub cut shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Benchmark Co. raised their target price on shares of BioTelemetry from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. BioTelemetry presently has a consensus rating of “Buy” and an average price target of $44.40.
In other news, Director Robert J. Rubin sold 15,000 shares of the business’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $28.14, for a total transaction of $422,100.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.60% of the stock is currently owned by insiders.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.